Author

Wei Sang

h-index 26 View on Semantic Scholar

We have 3 of 213 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Impact of IL-6 and ferritin dynamics on clinical outcomes after anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma patients

Background Interleukin-6 (IL-6) and ferritin are routinely monitored during chimeric antigen receptor T-cell (CAR-T) therapy; however, their temporal dynamics and outcome-specific relevance remain inadequately characterized. This study aimed to evaluate the value of IL-6 and ferritin at multiple time points in patients...

Ling Gao, Yan-Yan Mao, Cai Sun et al. · Frontiers in Immunology · 0 citations

Open access Sep 2026

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy.

Repeat infusion of chimeric antigen receptor (CAR) T-cell is effective for patients with refractory or relapsed multiple myeloma (RRMM) after failing a prior CAR Tcell therapy. It is unknown whether B-cell maturation antigen (BCMA) CAR T-cell is effective for patients with RRMM after anti-G protein-coupled receptor, cl...

Xiao-Tian Zhang, Fan Xia, Kun-Ming Qi et al. · Haematologica · 0 citations

Jul 2026

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

Third-generation anti-CD30 CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in r/r CD30+ lymphoma patients and addition of auto-HSCT following CAR T-cell therapy improves depth of remission and potentially enhances OS and PFS.

Xiang-Min Wang, Qing Zhang, Dong-Mei Yan et al. · Clinical Cancer Research · 0 citations